Brigham Does Not Contest Plaintiffs’ Offers of Proof as Morcellation Cases Proceed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This article is part of The Cancer Letter's How Medical Devices Do Harm series.

BRIGHAM & WOMEN’S HOSPITAL chose not to contest the plaintiffs’ offers of proof in two medical malpractice lawsuits against the Boston hospital at a Massachusetts tribunal May 13.

The two lawsuits related to power morcellation will now be allowed to proceed. The suits were filed by Richard Kaitz and Hooman Noorchashm, whose wives, Erica Kaitz and Amy Reed, had the controversial minimally invasive surgery at Brigham in 2012 and 2013, respectively.

The procedure, which until recently was performed in an estimated 100,000 women annually in the U.S., is the focal point of a two-year debate that has divided the surgical field. When a previously undiagnosed malignant tumor—usually a sarcoma—is present, the procedure spreads the cancerous tissue, upstaging the disease (The Cancer Letter, How Medical Devices Do Harm).

Erica died Dec. 7, 2013 from metastatic leiomyosarcoma, and Reed, formerly an anesthesiologist at Beth Israel Deaconess Medical Center, is undergoing treatment for stage IV disease.

“It’s a rare case that the defendant does not contest the plaintiff’s offer of proof at the tribunal stage,” said Tom Greene, the attorney representing Kaitz and Noorchashm’s families. Brigham did not respond to an email from The Cancer Letter by deadline.

Massachusetts law requires that a tribunal—consisting of a judge, an attorney, and a physician—review medical malpractice cases to screen out lawsuits that are not supported by clinical evidence or fact. The process determines whether there is sufficient evidence for the case to proceed.

According to the Massachusetts Medical Society, tribunals screen out approximately 16 percent of all medical malpractice cases in the state.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login